270 related articles for article (PubMed ID: 30556125)
1. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
3. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes.
Zhou Q; Pichlmeier S; Denz AM; Schreiner N; Straub T; Benitz S; Wolff J; Fahr L; Del Socorro Escobar Lopez M; Kleeff J; Mayerle J; Mahajan UM; Regel I
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240084
[TBL] [Abstract][Full Text] [Related]
4. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
Kalisz M; Bernardo E; Beucher A; Maestro MA; Del Pozo N; Millán I; Haeberle L; Schlensog M; Safi SA; Knoefel WT; Grau V; de Vas M; Shpargel KB; Vaquero E; Magnuson T; Ortega S; Esposito I; Real FX; Ferrer J
EMBO J; 2020 May; 39(9):e102808. PubMed ID: 32154941
[TBL] [Abstract][Full Text] [Related]
5. KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Noncanonical Activin Pathway.
Yi Z; Wei S; Jin L; Jeyarajan S; Yang J; Gu Y; Kim HS; Schechter S; Lu S; Paulsen MT; Bedi K; Narayanan IV; Ljungman M; Crawford HC; Pasca di Magliano M; Ge K; Dou Y; Shi J
Cell Mol Gastroenterol Hepatol; 2022; 13(2):643-667. PubMed ID: 34583087
[TBL] [Abstract][Full Text] [Related]
6. KDM6A Loss Recruits Tumor-Associated Neutrophils and Promotes Neutrophil Extracellular Trap Formation in Pancreatic Cancer.
Yang J; Jin L; Kim HS; Tian F; Yi Z; Bedi K; Ljungman M; Pasca di Magliano M; Crawford H; Shi J
Cancer Res; 2022 Nov; 82(22):4247-4260. PubMed ID: 36306422
[TBL] [Abstract][Full Text] [Related]
7. Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Andricovich J; Perkail S; Kai Y; Casasanta N; Peng W; Tzatsos A
Cancer Cell; 2018 Mar; 33(3):512-526.e8. PubMed ID: 29533787
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
[TBL] [Abstract][Full Text] [Related]
9. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma.
Li F; Si W; Xia L; Yin D; Wei T; Tao M; Cui X; Yang J; Hong T; Wei R
Mol Cancer; 2024 May; 23(1):90. PubMed ID: 38711083
[TBL] [Abstract][Full Text] [Related]
10. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
Zhang X; Zegar T; Weiser T; Hamdan FH; Berger BT; Lucas R; Balourdas DI; Ladigan S; Cheung PF; Liffers ST; Trajkovic-Arsic M; Scheffler B; Joerger AC; Hahn SA; Johnsen SA; Knapp S; Siveke JT
Int J Cancer; 2020 Nov; 147(10):2847-2861. PubMed ID: 32599645
[TBL] [Abstract][Full Text] [Related]
12. Histone acetylation of glucose-induced thioredoxin-interacting protein gene expression in pancreatic islets.
Bompada P; Atac D; Luan C; Andersson R; Omella JD; Laakso EO; Wright J; Groop L; De Marinis Y
Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):82-91. PubMed ID: 27989964
[TBL] [Abstract][Full Text] [Related]
13. WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC.
Pan Y; Lu F; Xiong P; Pan M; Zhang Z; Lin X; Pan M; Huang H
J Exp Clin Cancer Res; 2018 Jul; 37(1):167. PubMed ID: 30041660
[TBL] [Abstract][Full Text] [Related]
14. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression.
Quan M; Chen Z; Jiao F; Xiao X; Xia Q; Chen J; Chao Q; Li Y; Gao Y; Yang H; Wang L; Cui J
J Exp Clin Cancer Res; 2020 Jan; 39(1):13. PubMed ID: 31941533
[TBL] [Abstract][Full Text] [Related]
15. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα.
Yamamoto K; Tateishi K; Kudo Y; Sato T; Yamamoto S; Miyabayashi K; Matsusaka K; Asaoka Y; Ijichi H; Hirata Y; Otsuka M; Nakai Y; Isayama H; Ikenoue T; Kurokawa M; Fukayama M; Kokudo N; Omata M; Koike K
Carcinogenesis; 2014 Nov; 35(11):2404-14. PubMed ID: 24947179
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
Terashima M; Ishimura A; Wanna-Udom S; Suzuki T
Biochem Biophys Res Commun; 2017 Sep; 490(4):1407-1413. PubMed ID: 28698146
[TBL] [Abstract][Full Text] [Related]
17. Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
Leng X; Wang J; An N; Wang X; Sun Y; Chen Z
Oncogene; 2020 Oct; 39(41):6468-6479. PubMed ID: 32879445
[TBL] [Abstract][Full Text] [Related]
18. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Revia S; Seretny A; Wendler L; Banito A; Eckert C; Breuer K; Mayakonda A; Lutsik P; Evert M; Ribback S; Gallage S; Chikh Bakri I; Breuhahn K; Schirmacher P; Heinrich S; Gaida MM; Heikenwälder M; Calvisi DF; Plass C; Lowe SW; Tschaharganeh DF
Gut; 2022 Aug; 71(8):1613-1628. PubMed ID: 34509979
[TBL] [Abstract][Full Text] [Related]
19. Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma.
Bauden M; Kristl T; Sasor A; Andersson B; Marko-Varga G; Andersson R; Ansari D
BMC Cancer; 2017 Dec; 17(1):810. PubMed ID: 29197353
[TBL] [Abstract][Full Text] [Related]
20. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.
Hemming S; Cakouros D; Isenmann S; Cooper L; Menicanin D; Zannettino A; Gronthos S
Stem Cells; 2014 Mar; 32(3):802-15. PubMed ID: 24123378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
